Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Everolimus has been approved to be effective when used with exemestane after progression on
non-steroidal aromatase inhibitors in postmenopausal women based on the BOLERO-2 clinical
trial. However, the superiority of addition of everolimus to endocrine therapy hasn't been
established in the premenopausal women. This is a phase 2, multicentre clinical trial to
evaluate the role of everolimus in the first-line endocrine treatment of premenopausal MBC
patients after progression on tamoxifen.